Published in J Transl Med on September 02, 2014
The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. Immunity (2016) 0.81
Elevated Expression of CD160 and 2B4 Defines a Cytolytic HIV-Specific CD8+ T-Cell Population in Elite Controllers. J Infect Dis (2015) 0.80
Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors. Sci Rep (2016) 0.75
Increased CD160 expression on circulating natural killer cells in atherogenesis. J Transl Med (2015) 0.75
PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells. Front Immunol (2017) 0.75
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med (1998) 14.39
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med (2006) 13.15
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 13.00
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol (2003) 11.48
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2008) 10.26
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature (2004) 9.53
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60
Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature (2008) 5.94
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol (2003) 4.56
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol (2007) 4.41
LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity (1998) 4.23
B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol (2004) 3.49
CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol (2008) 2.99
Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog (2010) 2.91
Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem (1997) 2.33
LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol (2000) 2.27
A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci U S A (2005) 2.00
Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology (2006) 1.96
Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci U S A (2007) 1.88
Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem (1998) 1.60
T-cell exhaustion in HIV infection. Curr HIV/AIDS Rep (2008) 1.38
HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J Leukoc Biol (2009) 1.34
CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog (2012) 1.28
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol (2009) 1.22
A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity. J Exp Med (1993) 1.11
Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol (1998) 1.09
Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proc Natl Acad Sci U S A (2002) 1.08
Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset. J Immunol (2004) 1.00
Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells. Biochem Biophys Res Commun (2006) 0.99
Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells. J Immunol (1999) 0.98
Characterization of murine CD160+ CD8+ T lymphocytes. Immunol Lett (2006) 0.95
Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation. J Immunol (2009) 0.94
A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. J Exp Med (2011) 0.92
BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression. Int Immunol (2002) 0.90
A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity. J Immunol (2007) 0.86
Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation. J Invest Dermatol (2007) 0.83
Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT. J Mol Biol (2011) 0.82
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature (2003) 6.01
The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol (2010) 5.54
Congenital heart disease in the general population: changing prevalence and age distribution. Circulation (2007) 5.16
Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med (2010) 3.81
Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation (2014) 3.78
Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ (2008) 3.63
Cancer risk related to low-dose ionizing radiation from cardiac imaging in patients after acute myocardial infarction. CMAJ (2011) 3.15
Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation (2012) 2.96
Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: a review of randomized controlled trials. J Am Coll Cardiol (2005) 2.75
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68
Administrative Data Feedback for Effective Cardiac Treatment: AFFECT, a cluster randomized trial. JAMA (2005) 2.54
Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada. BMJ (2009) 2.50
Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med (2002) 2.45
Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures. CMAJ (2008) 2.23
The potential economic impact of restricted access to angiotensin-receptor blockers. CMAJ (2011) 2.22
Preoperative anxiety as a predictor of mortality and major morbidity in patients aged >70 years undergoing cardiac surgery. Am J Cardiol (2013) 2.18
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology (2011) 2.16
Bril: a novel bone-specific modulator of mineralization. J Bone Miner Res (2008) 2.11
Children and adults with congenital heart disease lost to follow-up: who and when? Circulation (2009) 2.10
Statins and cancer risk. Am J Med (2008) 2.09
Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology (2009) 2.07
Alternative smoking cessation aids: a meta-analysis of randomized controlled trials. Am J Med (2012) 2.06
Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol (2005) 2.03
Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ (2009) 2.02
Changing mortality in congenital heart disease. J Am Coll Cardiol (2010) 1.99
Traditional risk factors and a Genetic Risk Score are associated with age of first acute coronary syndrome. Heart (2014) 1.95
Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med (2012) 1.94
Atrial arrhythmias in adults with congenital heart disease. Circulation (2009) 1.94
Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med (2005) 1.91
Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. J Am Coll Cardiol (2013) 1.86
The nested case-control study in cardiology. Am Heart J (2003) 1.84
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J (2006) 1.82
Sex-related differences in access to care among patients with premature acute coronary syndrome. CMAJ (2014) 1.67
Specialized adult congenital heart disease care: the impact of policy on mortality. Circulation (2014) 1.67
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63
Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum (2008) 1.63
Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem (2002) 1.63
Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med (2002) 1.58
Life-course socioeconomic position and incidence of coronary heart disease: the Framingham Offspring Study. Am J Epidemiol (2009) 1.57
Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure--a population study. Eur J Heart Fail (2007) 1.57
Antibiotic self-stewardship: trainee-led structured antibiotic time-outs to improve antimicrobial use. Ann Intern Med (2014) 1.54
Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med (2003) 1.54
Class effects of statins in elderly patients with congestive heart failure: a population-based analysis. Am Heart J (2007) 1.53
Coarctation of the aorta and coronary artery disease: fact or fiction? Circulation (2012) 1.53
Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol (2005) 1.52
Emergence of sex differences in prevalence of high systolic blood pressure: analysis of a longitudinal adolescent cohort. Circulation (2006) 1.52
Updated risk factor values and the ability of the multivariable risk score to predict coronary heart disease. Am J Epidemiol (2004) 1.52
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother (2010) 1.49
In-hospital management of atrial fibrillation: the CHADS₂ score predicts increased cost. Can J Cardiol (2011) 1.46
Sex differences in acute coronary syndrome symptom presentation in young patients. JAMA Intern Med (2013) 1.45
Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors. Circulation (2013) 1.44
Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res (2005) 1.44
Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol (2005) 1.44
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ (2005) 1.43
Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line. J Virol (2004) 1.42
Angina with "normal" coronary arteries: sex differences in outcomes. Am Heart J (2007) 1.41
Lack of benefit for routine functional testing early after coronary artery bypass graft surgery: results from the ROSETTA-CABG Registry. J Invasive Cardiol (2006) 1.40
Utility of routine functional testing after percutaneous transluminal coronary angioplasty: results from the ROSETTA registry. J Invasive Cardiol (2004) 1.40
Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA (2012) 1.36
CCORT/CCS quality indicators for acute myocardial infarction care. Can J Cardiol (2003) 1.35
An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J Biol Chem (2003) 1.30
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology (2013) 1.28
Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells. J Med Chem (2004) 1.27
Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. J Clin Invest (2011) 1.27
Cardiovascular outcomes after a change in prescription policy for clopidogrel. N Engl J Med (2008) 1.27
Depression and prognosis following hospital admission because of acute myocardial infarction. CMAJ (2003) 1.25
Does aggressive care following acute myocardial infarction reduce mortality? Analysis with instrumental variables to compare effectiveness in Canadian and United States patient populations. Health Serv Res (2003) 1.23
Life course socioeconomic position is associated with inflammatory markers: the Framingham Offspring Study. Soc Sci Med (2010) 1.21
Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trials. Eur Heart J (2008) 1.20
Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J (2003) 1.20
T-cell tropism and the role of ORF66 protein in pathogenesis of varicella-zoster virus infection. J Virol (2005) 1.19
In-hospital cost of total hip arthroplasty in Canada and the United States. J Bone Joint Surg Am (2004) 1.19
Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes. Antimicrob Agents Chemother (2013) 1.18
Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives. Bioorg Med Chem Lett (2004) 1.18
Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein. J Virol (2012) 1.17
Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials. Am J Med (2011) 1.16
The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity. J Virol (2006) 1.15
Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. J Am Coll Cardiol (2003) 1.14
Ethnicity and sex affect diabetes incidence and outcomes. Diabetes Care (2010) 1.14
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology (2013) 1.14
Depression symptoms have a greater impact on the 1-year health-related quality of life outcomes of women post-myocardial infarction compared to men. Eur J Cardiovasc Nurs (2006) 1.14
Outcomes of acute myocardial infarction in Canada. Can J Cardiol (2003) 1.14
Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew Chem Int Ed Engl (2003) 1.13
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med (2009) 1.11
Gout, allopurinol use, and heart failure outcomes. Arch Intern Med (2010) 1.10
The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Arch Intern Med (2003) 1.08
In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob Agents Chemother (2011) 1.08